DK3174874T3 - Berberinsalte, ursodeoxycholsalte og kombinationer, fremgangsmåder til fremstilling og anvendelse deraf. - Google Patents

Berberinsalte, ursodeoxycholsalte og kombinationer, fremgangsmåder til fremstilling og anvendelse deraf. Download PDF

Info

Publication number
DK3174874T3
DK3174874T3 DK15826295.6T DK15826295T DK3174874T3 DK 3174874 T3 DK3174874 T3 DK 3174874T3 DK 15826295 T DK15826295 T DK 15826295T DK 3174874 T3 DK3174874 T3 DK 3174874T3
Authority
DK
Denmark
Prior art keywords
salts
ursodeoxycholic
combinations
preparation
methods
Prior art date
Application number
DK15826295.6T
Other languages
Danish (da)
English (en)
Inventor
Liping Liu
Original Assignee
Shenzhen Hightide Biopharmaceutical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Hightide Biopharmaceutical Ltd filed Critical Shenzhen Hightide Biopharmaceutical Ltd
Application granted granted Critical
Publication of DK3174874T3 publication Critical patent/DK3174874T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
DK15826295.6T 2014-07-29 2015-07-28 Berberinsalte, ursodeoxycholsalte og kombinationer, fremgangsmåder til fremstilling og anvendelse deraf. DK3174874T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462030147P 2014-07-29 2014-07-29
US201462030140P 2014-07-29 2014-07-29
US201562128077P 2015-03-04 2015-03-04
PCT/CN2015/085350 WO2016015634A1 (en) 2014-07-29 2015-07-28 Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof

Publications (1)

Publication Number Publication Date
DK3174874T3 true DK3174874T3 (da) 2020-12-07

Family

ID=55216773

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15826295.6T DK3174874T3 (da) 2014-07-29 2015-07-28 Berberinsalte, ursodeoxycholsalte og kombinationer, fremgangsmåder til fremstilling og anvendelse deraf.

Country Status (16)

Country Link
US (4) US10301303B2 (enExample)
EP (1) EP3174874B1 (enExample)
JP (4) JP6917144B2 (enExample)
KR (3) KR102573865B1 (enExample)
CN (2) CN106687460B (enExample)
AU (2) AU2015296098B2 (enExample)
BR (1) BR112017001623B1 (enExample)
CA (2) CA2945609C (enExample)
DK (1) DK3174874T3 (enExample)
EA (1) EA032971B1 (enExample)
ES (1) ES2835874T3 (enExample)
IL (3) IL294063B2 (enExample)
MX (3) MX373840B (enExample)
NZ (1) NZ728488A (enExample)
SG (1) SG11201700481YA (enExample)
WO (1) WO2016015634A1 (enExample)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9719068B2 (en) 2010-05-06 2017-08-01 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
EP3139910B1 (en) 2014-05-05 2019-11-27 The Board of Regents of The University of Texas System Compositions comprising ursolic acid and/or resveratrol for treating obesity
WO2015183794A1 (en) * 2014-05-27 2015-12-03 City Of Hope Tgr5 agonist complexes for treating diabetes and cancer
EP3149156B1 (en) 2014-05-28 2021-02-17 Children's Hospital Medical Center Methods and systems for converting precursor cells into gastric tissues through directed differentiation
NZ728488A (en) * 2014-07-29 2023-03-31 Shenzhen Hightide Biopharmaceutical Ltd Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof
JP6804438B2 (ja) 2014-10-17 2020-12-23 チルドレンズ ホスピタル メディカル センター 多能性幹細胞を使用するヒト小腸のｉｎ ｖｉｖｏモデル、並びにそれを作製、及び使用する方法
US20180050048A1 (en) * 2015-04-06 2018-02-22 SHENZHEN HJGHTIDE-BIOPHARMAGEUTiCAL, LTD. Conjugate compounds of ursodeoxycholic, berberine or l-carnitine, and compositions and methods thereof
US12137716B2 (en) 2015-04-16 2024-11-12 Michael Hudnall Methods of liver disease treatment
CN105168228B (zh) * 2015-11-04 2016-06-22 北京凯因科技股份有限公司 奥贝胆酸和小檗碱的复方组合物及其应用
CN106692973A (zh) * 2015-11-13 2017-05-24 深圳君圣泰生物技术有限公司 一种组合物及其用途、药物制剂
CN105693805A (zh) * 2016-03-15 2016-06-22 合肥华方医药科技有限公司 一种胆酸类小檗碱偶合物的制备及医药用途
CN105801663A (zh) * 2016-03-15 2016-07-27 合肥华方医药科技有限公司 一种熊果酸小檗碱偶合物的制备方法及医药用途
GB201605013D0 (en) * 2016-03-24 2016-05-11 Inst Of Food Res S-methylcysteine sulfoxide for prostate cancer treatment
ITUA20163025A1 (it) 2016-04-29 2017-10-29 Sochim Int S P A Composizione per il trattamento della sindrome dell’ovaio policistico
EP4177335A1 (en) 2016-05-05 2023-05-10 Children's Hospital Medical Center Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
CA3023648C (en) * 2016-05-10 2023-11-28 Shenzhen Hightide Biopharmaceutical, Ltd. Pharmaceutical composition of berberine with epa and dha
WO2017218004A1 (en) * 2016-06-17 2017-12-21 Michael Hudnall Medical food for patients with chronic liver disease
CN105963306B (zh) * 2016-07-05 2018-08-17 福州大学 一种具有协同抗肿瘤转移活性的药物组合物
US10729735B1 (en) 2016-09-14 2020-08-04 Phoenix Biotechnology, Inc. Method and compostitions for treating coronavirus infection
US10596186B2 (en) 2016-09-14 2020-03-24 Phoenix Biotechnology, Inc. Method and compositions for treating viral infections
EP3512524B1 (en) * 2016-09-14 2021-04-07 Phoenix Biotechnology, Inc. Method and compositions for treating viral infection
US10702567B2 (en) 2016-09-14 2020-07-07 Phoenix Biotechnology, Inc. Method and compositions for treating viral infection
US10703761B2 (en) * 2016-10-18 2020-07-07 City Of Hope Bile acid receptor modulators and methods of use thereof
EP3534976A4 (en) 2016-11-04 2020-09-16 Children's Hospital Medical Center PATHOLOGICAL MODELS OF HEPATIC ORGANOIDS AND ASSOCIATED METHODS OF MANUFACTURE AND USE
EP3548507A4 (en) 2016-12-05 2020-07-15 Children's Hospital Medical Center COLON ORGANOIDS AND PROCESSES FOR THE PREPARATION AND USE THEREOF
US10471007B2 (en) * 2016-12-16 2019-11-12 Jeffrey R Olynyk Sublingual therapeutic solutions and methods
IT201700032960A1 (it) 2017-03-24 2018-09-24 Akademy Pharma S R L Composto nutraceutico per il trattamento dell’eccesso di peso e della moderata ipercolesterolemia e disglicemia
US20230404107A1 (en) * 2017-03-28 2023-12-21 IRP Health Pty Ltd Berberine alkaloids in the prevention and/or treatment of intestinal disease
EP3609997A4 (en) 2017-04-14 2021-03-03 Children's Hospital Medical Center COMPOSITIONS OF STEM CELLS FROM MULTIPLE DONOR CELLS AND THEIR PREPARATION PROCEDURES
IL270162B2 (en) * 2017-04-25 2025-07-01 Buck Inst Res Aging ?-ketoglutarate (akg) and (i) a vitamin a compound, or (ii) a vitamin d compound, for use in delaying onset or delaying progression of frailty
CN108864077B (zh) * 2017-05-12 2020-05-22 深圳君圣泰生物技术有限公司 小檗碱有机酸盐的固体形式及其制备方法
WO2019023245A1 (en) * 2017-07-25 2019-01-31 Cedars-Sinai Medical Center METHODS OF TREATING HEPATIC DISEASES
CN111295203B (zh) * 2017-08-11 2022-09-06 深圳君圣泰生物技术有限公司 用于治疗炎症性肠病的方法和组合物
EP3694603A4 (en) 2017-10-10 2021-07-14 Children's Hospital Medical Center ESOPHAGUS TISSUE AND / OR ORGANOID COMPOSITIONS AND METHOD FOR MANUFACTURING THEREOF
JP2021504546A (ja) * 2017-11-29 2021-02-15 ビーエイエスエフ・ソシエタス・エウロパエアＢａｓｆ Ｓｅ 組成物、その製造方法および使用方法
US12379372B2 (en) 2017-12-21 2025-08-05 Children's Hospital Medical Center Digitalized human organoids and methods of using same
CN112543635A (zh) 2018-05-29 2021-03-23 Irp健康股份有限公司 硝基咪唑制剂
KR102887406B1 (ko) 2018-07-26 2025-11-19 칠드런즈 호스피탈 메디칼 센터 간-담도-췌장 조직 및 이를 제조하는 방법
WO2020056158A1 (en) 2018-09-12 2020-03-19 Children's Hospital Medical Center Organoid compositions for the production of hematopoietic stem cells and derivatives thereof
IL281761B2 (en) 2018-09-25 2025-09-01 Ponce De Leon Health Designated Activity Company Process for preparing calcium alpha-ketoglutarate
CN109303921B (zh) * 2018-10-30 2021-02-09 中国药科大学 Fxr激动剂与sirt1激动剂联用在制备抗肝纤维化药物中的应用
IT201800011155A1 (it) * 2018-12-17 2020-06-17 S&R Farm S P A uso di una miscela di berberina e resveratrolo per il controllo delle dislipidemie
CN111499626A (zh) * 2019-01-31 2020-08-07 西南大学 一种表小檗碱的合成方法及应用
CN109999034A (zh) * 2019-02-11 2019-07-12 浙江理工大学 肿瘤蛋白tnik激酶靶向天然小分子抑制剂及其应用
JP7598591B2 (ja) * 2019-03-01 2024-12-12 慶應義塾 Ｈｉｆ抑制用組成物
CN109806264B (zh) * 2019-04-10 2021-04-02 江苏海钥医药科技有限公司 药物组合物及其应用
CN112076199A (zh) * 2019-06-13 2020-12-15 谢亚坚 一种降血糖降血脂和降血胆固醇方剂
CN110368392A (zh) * 2019-08-20 2019-10-25 延边大学 科罗索酸在制备抗肝损伤药物或抗肝损伤保健品中的应用
CN112851660B (zh) * 2019-11-12 2022-03-18 广东药科大学 含有小檗碱的酸-碱加成盐、其制备方法及其作为药物的用途
CN111116578B (zh) * 2019-12-26 2021-06-04 深圳市老年医学研究所 去亚甲基小檗碱的制备方法及其应用
KR102150821B1 (ko) * 2020-01-22 2020-09-03 주식회사 에이스바이오메드 간 질환 치료용 또는 치료 효과 증진을 위한 콜히친 복합제제
US11806359B2 (en) 2020-03-31 2023-11-07 Phoenix Biotechnology, Inc. Method and compositions for treating Coronavirus infection
US20230181547A1 (en) * 2020-05-15 2023-06-15 Nguyen Anh VAN Solid lipid nano-composition containing berberine and cinnamonaldehyde effective in treating diabetes, dyslipidemia, and method of preparing the same
US11957649B2 (en) 2020-06-02 2024-04-16 Glykon Technologies Group, Llc Methods and pharmaceutical preparations for elevating ketone utilization
JP7741169B2 (ja) * 2020-08-12 2025-09-17 アーチャー－ダニエルズ－ミッドランド カンパニー ２，５－フランジカルボン酸ジメチルエステル、及びその他のエステル化生成物の精製
CN114195850B (zh) * 2020-09-18 2024-08-16 成都贝诺科成生物科技有限公司 一种用于防治肝病的化合物及其制药用途
KR102636847B1 (ko) * 2020-09-18 2024-02-19 경북대학교 산학협력단 티아민 유도체를 포함하는 이식편대숙주질환 예방 또는 치료용 약학적 조성물
WO2022083713A1 (en) * 2020-10-23 2022-04-28 Shenzhen Hightide Biopharmaceutical Ltd. Compositions of berberine ursodeoxycholate and methods thereof for treating fatty liver disease, diabetes and hyperlipidemia
WO2022161468A1 (en) * 2021-01-28 2022-08-04 Shenzhen Hightide Biopharmaceutical Ltd. Compositions of berberine ursodeoxycholate and methods thereof for treating primary sclerosing cholangitis
CN113143962B (zh) * 2021-05-11 2022-08-05 四川九章生物科技有限公司 一种治疗高脂血症的药物组合物及其制备方法
WO2023027994A1 (en) * 2021-08-23 2023-03-02 Paxmedica, Inc. Methods for treating nervous system disorders with antipurinergic agents
CN113577064B (zh) * 2021-09-09 2023-07-04 浙江中医药大学 一种增强肿瘤免疫的联合用药物组合物及其应用
JPWO2023074894A1 (enExample) * 2021-11-01 2023-05-04
WO2023091173A1 (en) * 2021-11-16 2023-05-25 Michael Hudnall Methods of liver disease treatment
WO2023088463A1 (en) * 2021-11-22 2023-05-25 Shenzhen Hightide Biopharmaceutical Ltd. Compositions and methods of berberine ursodeoxycholate for modulating gut microbiome compositions
CN116178384A (zh) * 2021-11-29 2023-05-30 湖南师范大学 四种小檗碱中短链脂肪酸盐的制备
CN114716498B (zh) * 2022-01-20 2024-01-23 成都贝诺科成生物科技有限公司 一种高稳定性的失碳熊去氧胆酸小檗碱盐晶型及其制备方法
KR20230156533A (ko) * 2022-05-06 2023-11-14 동아대학교 산학협력단 이소퀴놀린 유도체 화합물을 유효성분으로 포함하는 미토파지 활성 촉진용 조성물 및 이의 용도
EP4547256A1 (en) * 2022-07-01 2025-05-07 Intercept Pharmaceuticals, Inc. Methods for ameliorating cognitive impairment using bile acid derivatives
CN115011661B (zh) * 2022-07-22 2024-06-21 湖南科瑞生物制药股份有限公司 一种3β-熊去氧胆酸的合成方法
KR102828609B1 (ko) * 2022-10-11 2025-07-02 주식회사 알트메디칼 이소퀴놀린 유도체를 유효성분으로 포함하는 파킨슨병의 예방 또는 치료용 조성물
KR20240052403A (ko) * 2022-10-14 2024-04-23 주식회사 알트메디칼 이소퀴놀린 유도체를 유효성분으로 포함하는 말초신경병증의 예방 또는 치료용 조성물
KR20240054685A (ko) * 2022-10-19 2024-04-26 주식회사 알트메디칼 이소퀴놀린 유도체를 유효성분으로 포함하는 멜라스증후군의 예방 또는 치료용 조성물
WO2024120452A1 (en) * 2022-12-07 2024-06-13 Shenzhen Hightide Biopharmaceutical Ltd. Compositions and methods for prophylaxis and treatment of covid-19
EP4642454A1 (en) * 2022-12-30 2025-11-05 Shenzhen Hightide Biopharmaceutical Ltd. Pharmaceutical combinations and compositions, and methods of use thereof
KR20250166895A (ko) * 2023-02-15 2025-11-28 센젠 하이타이드 바이오파마슈티컬 리미티드 베르베린 타우로우르소데옥시콜레이트 조성물 및 이의 방법
WO2024179570A1 (en) * 2023-03-01 2024-09-06 Shenzhen Hightide Biopharmaceutical Ltd. Compositions and methods for treating severe hypertriglyceridemia
WO2024222408A1 (zh) * 2023-04-28 2024-10-31 杭州居维叶生物医药有限公司 一种黄连素维生素c盐组合物、制备方法及其应用
WO2024245370A1 (zh) * 2023-05-31 2024-12-05 上海复宏汉霖生物技术股份有限公司 一种组合产品、盐及其用途
WO2024245371A1 (zh) * 2023-05-31 2024-12-05 上海复宏汉霖生物技术股份有限公司 一种组合产品、盐及其用于治疗神经退行性疾病或病症的用途
CN116850186A (zh) * 2023-06-02 2023-10-10 深圳市第二人民医院(深圳市转化医学研究院) 一种多靶点神经元保护剂在防治神经系统退行性疾病中的应用
WO2025053283A1 (ja) * 2023-09-07 2025-03-13 株式会社マイトジェニック ベルベルビン関連化合物
CN117398395B (zh) * 2023-12-14 2024-02-09 成都贝诺科成生物科技有限公司 失碳熊去氧胆酸小檗碱盐在制备预防和/或治疗消化道炎症的药物中的用途
WO2025130826A1 (en) * 2023-12-18 2025-06-26 Institute Of Medicinal Biotechnology, Chinese Academy Of Medical Sciences Compositions and methods for treating cancer
KR20250116419A (ko) * 2024-01-25 2025-08-01 주식회사 알트메디칼 이소퀴놀린 유도체 화합물을 유효성분으로 포함하는 당뇨병성 신증의 예방 또는 치료용 약학적 조성물
CN120267634A (zh) * 2025-04-09 2025-07-08 中国药科大学 一种外泌体融合肝靶向脂质体递药系统及其制备方法和应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5529075B2 (enExample) * 1971-08-20 1980-07-31
IT1136624B (it) 1981-05-21 1986-09-03 Erregierre Ind Chim Spa Prodotti di salificazione di acidi colici,processo per la loro preparazione e composizioni terapeutiche che li comprendono come principio attivo
JPS60163897A (ja) 1984-02-06 1985-08-26 Tokyo Tanabe Co Ltd ウルソデオキシコ−ル酸メグルミン塩およびその注射剤
JPS6256192A (ja) 1985-09-06 1987-03-11 Hitachi Ltd 感熱転写材
IT1245889B (it) 1991-04-12 1994-10-25 Alfa Wassermann Spa Formulazioni farmaceutiche per uso orale gastroresistenti contenenti sali di acidi biliari.
JPH06256192A (ja) 1993-03-05 1994-09-13 Nitsusui Seiyaku Kk 液状薬剤の製造法
FR2796551B1 (fr) * 1999-07-23 2003-07-25 Lipha Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant
KR20050081477A (ko) 2004-02-13 2005-08-19 켐젠주식회사 암로디핀 담즙산염, 그의 제조방법 및 이를 함유하는경구투여용 약학 조성물
CN1759834B (zh) 2004-09-17 2010-06-23 中国医学科学院医药生物技术研究所 黄连素或其与辛伐他汀联合在制备用于预防或治疗与血脂有关疾病或症状的产品中用途
CN1762367A (zh) 2004-10-18 2006-04-26 孙民富 熊去氧胆酸滴丸的处方及其制作方法
US20070032555A1 (en) 2005-07-01 2007-02-08 Concert Pharmaceuticals Inc. Novel aryloxyphenyl-propanamines
WO2007005644A2 (en) 2005-07-01 2007-01-11 Concert Pharmaceuticals Inc. Novel aryloxypropanamines
JP2009502961A (ja) 2005-07-29 2009-01-29 コンサート ファーマシューティカルズ インコーポレイテッド 新規な医薬組成物
JP5301991B2 (ja) 2005-07-29 2013-09-25 コンサート ファーマシューティカルズ インコーポレイテッド 新規なベンゾ［ｄ］［１，３］−ジオキソール誘導体
CA2640414C (en) * 2006-02-09 2013-07-09 National Research Council Of Canada Combinations of botanical extracts for promoting cardiovascular health
CN100509840C (zh) 2006-05-10 2009-07-08 华中科技大学 浙贝乙素和胆汁酸的衍生物及药物组合物
CN101113149B (zh) * 2006-07-25 2011-04-27 复旦大学 小檗碱类生物碱的脂肪族有机酸盐及其制备方法和应用
EP2116612B1 (en) * 2007-02-28 2017-08-30 DENKA SEIKEN Co., Ltd. Reagent for determination of quantity of small dense low-density lipoprotein
AU2008299921B2 (en) * 2007-09-13 2012-03-01 Concert Pharmaceuticals, Inc. Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof
CA2723132C (en) 2008-05-01 2014-04-08 Afexa Life Sciences Inc. Pharmaceutical composition comprising extracts of huanglian and ku ding cha effective for lowering blood lipid levels
IT1393095B1 (it) * 2009-02-19 2012-04-11 Prodotti Chimici Alimentari Processo per la sintesi del sale disodico dell'acido ursodesossicolico 3,7-disolfato.
RU2011139643A (ru) * 2009-03-17 2013-04-27 Акскан Фарма, Инк. Способ лечения неалкогольного стеатогепатита повышенными дозами урсодезоксихолевой кислоты
JP2010246578A (ja) * 2009-04-10 2010-11-04 Utsunomiya Univ 血中コレステロールの検査方法および検査装置
US20100323031A1 (en) * 2009-06-22 2010-12-23 Glykon Technologies Group, Llc Synergistic combination to enhance blood glucose and insulin metabolism
CN101987860B (zh) * 2009-08-06 2011-12-14 中山百灵生物技术有限公司 一种熊去氧胆酸的制备方法
CN101879162A (zh) * 2010-02-23 2010-11-10 江苏格林生物科技有限公司 一种α-亚麻酸乙酯配伍小檗碱的减肥物
CN102869382A (zh) * 2010-06-10 2013-01-09 (株)Ad生物技 通过抑制肠内胆固醇吸收而抑制高脂血症和肥胖症的组合物
CN101935319A (zh) * 2010-09-09 2011-01-05 陕西科技大学 一种黄连素有机酸盐和黄连素有机酸盐包合物及其制备方法
CN102078418B (zh) 2011-01-14 2012-04-18 广东药学院 一种防治脂代谢紊乱的复方中药提取物及其制备方法
CN102225961A (zh) 2011-04-21 2011-10-26 东北林业大学 小檗碱9位偶合胆酸新衍生物及其制备方法
CN102370643A (zh) 2011-07-20 2012-03-14 吉林敖东集团大连药业股份有限公司 盐酸小檗碱药物组合物及其制备方法
JP2014530816A (ja) * 2011-10-14 2014-11-20 ノバルティスアーゲー Ｗｎｔ経路関連疾患のための抗体および方法
CN102580087B (zh) * 2012-03-08 2013-08-21 董萍 一种可用于人体局部减肥和美体的原位脂肪细胞系复合抑制剂及其制备方法
CN103319479B (zh) * 2012-03-20 2015-08-26 王从品 大黄酸小檗碱离子对化合物、制备方法及应用
US8652518B2 (en) 2012-04-15 2014-02-18 Jahahreeh Finley Compositions and methods for the prevention and treatment of diseases or conditions associated with oxidative stress, inflammation, and metabolic dysregulation
CN102702190B (zh) * 2012-07-02 2016-04-27 东北制药集团股份有限公司 一种小檗碱静电复合物及其制备方法
JP2015533483A (ja) * 2012-09-07 2015-11-26 サノフイ メタボリックシンドロームを治療するための融合タンパク質
WO2014183184A1 (en) 2013-05-14 2014-11-20 University Of Prince Edward Island Compositions and methods for treating cardiometabolic diseases and disorders
CN103989677A (zh) 2013-12-20 2014-08-20 中国药科大学 去亚甲基小檗碱在制备降血糖药物中的应用
US20150284406A1 (en) * 2014-04-04 2015-10-08 North American Biomedical Research Center Usa, Inc Berberine-ursodeoxycholic acid conjugate for treating the liver
WO2015183794A1 (en) * 2014-05-27 2015-12-03 City Of Hope Tgr5 agonist complexes for treating diabetes and cancer
NZ728488A (en) * 2014-07-29 2023-03-31 Shenzhen Hightide Biopharmaceutical Ltd Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof

Also Published As

Publication number Publication date
AU2019222911B2 (en) 2021-05-20
KR20230019267A (ko) 2023-02-08
JP2020073546A (ja) 2020-05-14
IL294063B1 (en) 2024-08-01
AU2019222911A1 (en) 2019-09-19
KR20230134598A (ko) 2023-09-21
NZ728488A (en) 2023-03-31
EA032971B1 (ru) 2019-08-30
AU2015296098B2 (en) 2019-06-27
IL250317B (en) 2021-04-29
IL282156A (en) 2021-05-31
IL294063B2 (en) 2024-12-01
JP6917144B2 (ja) 2021-08-11
MX2017001372A (es) 2017-08-21
EP3174874A4 (en) 2019-03-13
MX2022009595A (es) 2022-09-02
MX2019013426A (es) 2020-02-07
EP3174874B1 (en) 2020-09-02
JP7285903B2 (ja) 2023-06-02
IL250317A0 (en) 2017-03-30
US20210300915A1 (en) 2021-09-30
AU2015296098A1 (en) 2016-11-03
CA2945609C (en) 2023-05-23
EA201790124A1 (ru) 2017-07-31
WO2016015634A1 (en) 2016-02-04
CA2945609A1 (en) 2016-02-04
MX373840B (es) 2020-03-25
SG11201700481YA (en) 2017-02-27
KR20250008786A (ko) 2025-01-15
KR102573865B1 (ko) 2023-09-05
US20190211007A1 (en) 2019-07-11
CA3194562A1 (en) 2016-02-04
BR112017001623A2 (pt) 2017-11-21
ES2835874T3 (es) 2021-06-23
JP2023099689A (ja) 2023-07-13
EP3174874A1 (en) 2017-06-07
IL282156B (en) 2022-07-01
CN106687460A (zh) 2017-05-17
US10988471B2 (en) 2021-04-27
US11976063B2 (en) 2024-05-07
BR112017001623B1 (pt) 2022-11-29
US20170037043A1 (en) 2017-02-09
IL294063A (en) 2022-08-01
JP2022020854A (ja) 2022-02-01
US11685735B2 (en) 2023-06-27
JP2017522264A (ja) 2017-08-10
CN110179792A (zh) 2019-08-30
US20230295151A1 (en) 2023-09-21
US10301303B2 (en) 2019-05-28
CN106687460B (zh) 2019-05-17

Similar Documents

Publication Publication Date Title
DK3174874T3 (da) Berberinsalte, ursodeoxycholsalte og kombinationer, fremgangsmåder til fremstilling og anvendelse deraf.
IL304772A (en) Antibodies, uses and methods
IL264454A (en) Novel compositions, uses and methods for making them
DK3161124T3 (da) Endofytter, associerede sammensætninger og fremgangsmåder til anvendelse deraf
IL274891A (en) Compositions, kits, and methods to induce acquired cytoresistance using stress protein inducers
PL3181560T3 (pl) Pochodna pirydynoamidopirymidyny, sposób jej otrzymywania i zastosowanie
IL250588B (en) Metrology method, target and substrate
DK3227336T3 (da) Anti-CD79b-antistoffer og fremgangsmåder til anvendelse
BR112016018521A2 (pt) composição, e, kit.
DK3139979T3 (da) Enhed, forstøver og fremgangsmåde
DK3154594T3 (da) Fap-aktiverede, terapeutiske midler og anvendelser i forbindelser dermed
BR112016026939A2 (pt) aparelho e método.
DK3137168T3 (da) Substituerede 4-phenylpiperidiner, deres fremstilling og anvendelse
SG11201608711RA (en) Material itq-55, method for preparation and use
LT3240895T (lt) Kompozicijos ir būdai, skirti baltymų glikozilinimui
DK3204386T3 (da) Substituerede aminopurinforbindelser, sammensætninger deraf og fremgangsmåder til behandling dermed
LT3168219T (lt) Piridono dariniai, turintys tetrahidropiranilmetilo grupę
PT3265123T (pt) Anticorpos, usos e métodos
IL256833A (en) Il-17f-specific capture agents, compositions, and methods of using and making
BR112016021230A2 (pt) dispositivos e métodos para preparar e/ou imergir chá.
IL268570B (en) Oligonucleotide compositions and methods of making the same
DK3236934T3 (da) Farmaceutisk sammensætning, fremstilling og anvendelser deraf
DK3302802T3 (da) Prøvebehandlingsindretninger, og fremgangsmåder til anvendelse deraf
LT3147352T (lt) Būdas, skirtas paruošti indikuotas pluripotentines kamienines ląsteles iš mezenchiminių kamieninių ląstelių naudojant florotanino frakciją
HRP20180773T1 (hr) Otopine sildenafila, te postupci njihove priprave i upotrebe